// App-Quantinova.ai

9528.0 : Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).

Researchers

Presenter

  • Xin Zhao

Principal Investigators

  • Linling Jin

  • Man Yu

  • Qiuxiang Ou

  • Hua Bao

  • Xue Wu

  • Yang Shao

  • Min Fan

Medical Centers

  • Department of Rehabilitation Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China

  • Translational Medicine Research Institute, Geneseeq Technology Inc, Toronto, ON, Canada

  • Geneseeq Technology Inc., Nanjing, China

  • Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China

Locations

  • China

  • Canada

Companies

  • Geneseeq Technology

  • Nanjing Geneseeq Tec

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Epidermal growth factor receptor

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved